To lower dog allergy reactions, a lot of efforts have been made to lower the allergen level in the environment. However, dog allergy is still lack of effective treatments. Immunotherapy may act as a solution to it.
Studies investigating dog allergen immunotherapy during the past 40 years have failed to demonstrate any clearly reproducible clinical evidence to confirm its effectiveness in ameliorating symptoms of rhinitis and asthma. Despite these data, US allergists typically include dog extracts in aeroallergen immunotherapy for sensitized patients. Future research is necessary to produce more potent and complex extracts that could be tailored to an individual patient's pattern of dog sensitization, but the first step would be to produce a standardized extract for clinical use. There after, additional trials could be designed to evaluate the efficacy of dog allergen immunotherapy in improving clinical end points for patients rather than merely changing their immunologic parameters.
Properly powered studies with consistent allergen extracts also would facilitate identification of the optimal dose required to produce these effects, if one exists. Until that time, the current recommendation on immunotherapy dosing for nonstandardized dog extracts is 15 mg of Can f 1 per dose; with the current extracts available in the United States, this can be obtained only with a 0.5-mL dose using full-strength (1:100 w/v) AP dog extract.
Smith D M, Coop C A. Dog allergen immunotherapy: past, present, and future[J]. Annals of Allergy, Asthma & Immunology, 2016.
Custovic A et al. Domestic allergens in public places. II: dog (Can f 1) and cockroach (Bla g 2) allergens in dust and mite, cat, dog and cockroach allergens in the air in public buildings. Clin Exp Allergy. 1996;26:1246e1252.